Notably, among four CKD–MBD biomarkers, patients with DM had significantly lower FGF23 levels (462 [127–1790] vs. 1237 [251–3120] pg/mL, p = 0.028). This evidence concerns the gene FGF23 and Marchiafava-Bignami disease.